HUTCHMED to Announce 2024 Final Results
Rhea-AI Summary
HUTCHMED (Nasdaq/AIM: HCM; SEHK:13) has scheduled the announcement of its 2024 final results for Wednesday, March 19, 2025, at 7:00 am EDT / 11:00 am GMT / 7:00 pm HKT. The company will host two conference calls with audio webcasts: an English presentation at 8:00 am EDT on March 19, and a Chinese (Putonghua) presentation at 8:30 pm EDT on the same day.
The presentation materials will be available for download before the conference calls on the company's website. Both webcasts can be accessed at www.hutch-med.com/event/, and a replay will be made available after the events.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, HCM gained 8.09%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2024 on Wednesday, March 19, 2025 at 7:00 am Eastern Daylight Time (EDT) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT).
Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management.
The English conference call and audio webcast will take place at 8:00 am EDT / 12:00 pm GMT / 8:00 pm HKT on Wednesday, March 19, 2025. In addition to the usual English webcast, there will also be a Chinese (Putonghua) webcast at 12:30 am GMT / 8:30 am HKT on Thursday, March 20, 2025 (8:30 pm EDT on Wednesday, March 19, 2025). Both webcasts will be available live via the company website at www.hutch-med.com/event/. The presentation will be available for downloading before the conference call begins. Details of the conference call dial-in will be provided in the financial results announcement and on the company website. A replay will also be available on the website shortly after the event.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception, HUTCHMED has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
CONTACTS
| Investor Enquiries | +852 2121 8200 / ir@hutch-med.com |
| Media Enquiries | |
| FTI Consulting – | +44 20 3727 1030 / HUTCHMED@fticonsulting.com |
| Ben Atwell / Alex Shaw | +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
| Panmure Liberum | Nominated Advisor and Joint Broker |
| Atholl Tweedie / Freddy Crossley / Rupert Dearden | +44 20 7886 2500 |
| HSBC | Joint Broker |
| Simon Alexander / Alina Vaskina / Arnav Kapoor | +44 20 7991 8888 |
| Cavendish | Joint Broker |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
FAQ
When will HUTCHMED (HCM) release its 2024 annual financial results?
What time is HUTCHMED's (HCM) English earnings call for 2024 results?
When is HUTCHMED's (HCM) Chinese language earnings call scheduled?
Where can I access HUTCHMED's (HCM) 2024 earnings presentation materials?
